Bruce Booth

Bruce is a Co-Founder and the Chairman of the Board at Kymera Therapeutics. He's also a partner at Atlas Venture and focuses on the discovery and development of novel therapeutics. Since joining in 2005, Bruce has been instrumental in forming unique, innovative, and capital-efficient structures for drug discovery and development. He is a co-founder/founding investor and currently chair of the board of miRagen Therapeutics, Nimbus Therapeutics, Padlock Therapeutics, Quartet Medicine, and Rodin Therapeutics. Along with Peter Barrett, Bruce seeded, incubated, and serves on the board of Zafgen (NASDAQ: ZFGN), and Bruce is a board member of Lysosomal Therapeutics Inc. (LTI) and Unum Therapeutics. Previously, he served on the boards of past Atlas companies Avila Therapeutics (acquired by Celgene), Stromedix (acquired by Biogen), Prestwick (acquired by Biovail), and Proprius (acquired by Cypress Biosciences), among others. Previously, Bruce was a principal at Caxton Health Holdings L.L.C., a healthcare-focused investment firm, where he focused on the firm’s private equity activities, ranging from early-stage venture capital through late-stage buyouts. Prior to Caxton, he was an associate principal at McKinsey & Company, a global strategic management consulting firm, where he advised clients on R&D productivity, corporate strategy and business development issues across the biopharmaceutical sector. Bruce currently serves as a trustee of the New York Academy of Medicine and is a term member of the council on foreign relations. He received a DPhil from Oxford University as a Marshall Scholar and a BS from the Pennsylvania State University.